About Biodel (NASDAQ:ALBO)
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:ALBO
- CUSIP: N/A
- Web: www.albireopharma.com
- Market Cap: $249.96 million
- Outstanding Shares: 8,882,000
- 50 Day Moving Avg: $23.31
- 200 Day Moving Avg: $22.40
- 52 Week Range: $14.00 - $37.69
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.12
- P/E Growth: 0.00
- Annual Revenue: $3.27 million
- Price / Sales: 75.67
- Book Value: $8.49 per share
- Price / Book: 3.28
- Current Ratio: 8.64%
- Quick Ratio: 8.64%
- Average Volume: 18,625 shs.
- Beta: 1.43
- Short Ratio: 1.32
Frequently Asked Questions for Biodel (NASDAQ:ALBO)
What is Biodel's stock symbol?
Biodel trades on the NASDAQ under the ticker symbol "ALBO."
How were Biodel's earnings last quarter?
Biodel Inc. (NASDAQ:ALBO) announced its quarterly earnings results on Monday, August, 21st. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.02. View Biodel's Earnings History.
Where is Biodel's stock going? Where will Biodel's stock price be in 2017?
5 analysts have issued 1 year target prices for Biodel's stock. Their forecasts range from $35.00 to $58.00. On average, they expect Biodel's stock price to reach $46.50 in the next twelve months. View Analyst Ratings for Biodel.
Who are some of Biodel's key competitors?
Some companies that are related to Biodel include uniQure N.V. (QURE), Clementia Pharmaceuticals (CMTA), Invacare Corporation (IVC), Entellus Medical (ENTL), Sucampo Pharmaceuticals (SCMP), Surgery Partners (SGRY), Jounce Therapeutics (JNCE), Tabula Rasa Healthcare (TRHC), MannKind Corporation (MNKD), BioCryst Pharmaceuticals (BCRX), Selecta Biosciences (SELB), Enzo Biochem (ENZ), Exactech (EXAC), Progenics Pharmaceuticals (PGNX), NuCana PLC Sponsored ADR (NCNA), Atara Biotherapeutics (ATRA), Pharming Group (PHGUF) and Adamas Pharmaceuticals (ADMS).
How do I buy Biodel stock?
Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biodel's stock price today?
MarketBeat Community Rating for Biodel (NASDAQ ALBO)MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Biodel stock can currently be purchased for approximately $27.86.
Earnings History for Biodel (NASDAQ:ALBO)Earnings History by Quarter for Biodel (NASDAQ ALBO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Biodel (NASDAQ:ALBO)
2017 EPS Consensus Estimate: ($3.37)
2018 EPS Consensus Estimate: ($3.06)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)
Insider Ownership Percentage: 22.30%Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Institutional Ownership Percentage: 27.36%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/20/2013||Brian Jg Pereira||Director||Sell||4,734||$2.26||$10,698.84|| |
Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
Loading headlines, please wait.
Biodel (ALBO) Chart for Tuesday, October, 24, 2017